IBEX Technologies Signs Definitive Agreement for Sale of the Company for $1.45 Cash Per Share
MONTREAL, Feb. 12, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) is pleased to announce...
Pharmaceutical
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on...
AlzeCure Pharma Broadcasts Live Expert Event on Alzheimer’s Around Highly Current Gamma-Secretase Modulators
STOCKHOLM, SE / ACCESSWIRE / February 12, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR),...
Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS
Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)Former...
Red Light Holland and PharmAla to Collaborate on Medical Psilocybin Development
PharmAla will consult on GMP Drug Product and Regulatory Development for Red Light Holland Toronto, Ontario--(Newsfile Corp. - February 9,...
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
OneMedNet Sees Real World Data Growth in Women’s Health
MINNEAPOLIS, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade...
iZafe Group’s Year-end Report, October-December 2023
STOCKHOLM, SWEDEN / ACCESSWIRE / February 9, 2024 / iZafe Group (STO:IZAFE-B) iZafe Group AB (publ.) presents today, February 9,...
Intellipharmaceutics International Inc. Announces Stock Option Grant
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company...
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
Revenues increased 7% compared to quarter from prior year and 15% from prior quarterImprovement in gross margin for quarter of...
Belhaven Biopharma Announces Groundbreaking Clinical Results for Nasdepi, the Revolutionary Nasal Dry Powder Epinephrine Product
News of the Successful Trial Comes Amid an Oversubscribed Investor Round and Preparation for Series A Financing RoundRALEIGH, NC /...
GE HealthCare and MedQuest Associates Collaborate to Provide Innovative Medical Device Technology and Digital Tools for Outpatient Imaging Centers
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MedQuest Associates (MedQuest),...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
Financials for Third Quarter Fiscal Year 2024 Ended December 31, 2023 will be released on February 14, 2024NORTHVALE, NJ /...
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Jones Healthcare Group’s Qube Pro Wins Prestigious PAC Global Awards
Innovation and Sustainability Lead to Double Award Win for Qube Pro at PAC GlobalLondon, Ontario--(Newsfile Corp. - February 8, 2024)...
Veru Reports Fiscal 2024 First Quarter Financial Highlights
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight...
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse...
Medexus Announces Fiscal Q3 2024 Results
Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 millionManagement to host...
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA...
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company...